Louisiana Senate Bill Would Bar Licensing Boards From Restricting Prescriber Access to Compounded Peptides
Louisiana Senate Bill 253, introduced by Sen. McMath in the 2026 Regular Session, would enact a new state law prohibiting professional and occupational licensing boards from stopping a prescribing healthcare provider from supplying patients with peptides sourced from an FDA-registered 503B outsourcing facility or a 503A compounding pharmacy that buys its active ingredients from an FDA-registered manufacturer — with the requirement that any peptide prescribed under the law not appear on the FDA's prohibited compounding list.
This is a summary. The reporting is Louisiana State Legislature's, and the link below goes to the original article.